Semaglutide vs Tirzepatide: Which GLP-1 Produces More Weight Loss?

How They Work Differently

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a gut hormone that suppresses appetite, slows gastric emptying, improves insulin secretion, and reduces "food noise" — the persistent mental preoccupation with eating. It acts on a single receptor class.

Tirzepatide is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. It activates both GLP-1 and GIP receptors simultaneously. GIP is a second incretin hormone involved in fat cell metabolism, energy storage regulation, and insulin secretion in fat tissue. The combined receptor activation produces more comprehensive metabolic effects than GLP-1 alone — and clinically, substantially greater weight loss.

STEP-1 vs SURMOUNT-1: The Clinical Evidence

The head-to-head clinical data is decisive. In STEP-1 (NEJM, 2021), adults with obesity without diabetes taking semaglutide 2.4mg weekly achieved an average 14.9% body weight loss over 68 weeks. 86.4% achieved ≥5% weight loss and 69.1% achieved ≥10%. These are strong outcomes by any historical pharmacological standard.

In SURMOUNT-1 (NEJM, 2022), adults with obesity without diabetes taking tirzepatide 15mg weekly achieved an average 22.5% body weight loss over 72 weeks — the largest pharmacological weight reduction ever recorded in a major clinical trial. 91% achieved ≥5% weight loss and 57% achieved ≥20% — an outcome historically achievable only with bariatric surgery. A 2023 real-world analysis in JAMA Internal Medicine confirmed tirzepatide superiority over semaglutide across every BMI category at every dose comparison over 12 months.

Side Effects: What's Different

Both share similar GI side effects driven by their shared GLP-1 mechanism — nausea (most common, weeks 1–8), constipation, fatigue, and occasionally vomiting. These are worse during dose escalation and typically diminish as the body adjusts. Both carry the same serious contraindications: not appropriate for patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).

Tirzepatide's GIP component may produce a slightly different tolerability experience in some patients — the nausea profile is generally similar but some patients report differences in the severity of specific GI effects. There is no consistent clinical evidence that one is tolerated significantly better than the other at equivalent stages of therapy.

Which Should You Choose at NewSelf?

For maximum weight loss and you are metabolically eligible without contraindications: the clinical evidence strongly supports Tirzepatide Plus⁺ at $144.49/month. The $44.52/month premium over semaglutide is justified by meaningfully superior average outcomes across all studied populations.

Choose Semaglutide Plus⁺ at $99.97/month if: budget is the primary constraint, your provider recommends starting with a first-line GLP-1, you have specific tolerability concerns, or you want to establish response to GLP-1 therapy before potentially stepping up to the dual agonist. Both are clinically excellent options at NewSelf's price points relative to the market. The NewSelf GLP-1 program offers both at flat dosage pricing — your physician will help determine which is appropriate for your specific health profile.